GlassScriptPhysician profile
Susan L Warner
NPI 1801888383
$2,421.26
in general payments reported to CMS, 2019-2025
28 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $223 · 2021: $201 · 2022: $713 · 2023: $532 · 2024: $238 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.23 |
| Education | $101.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $423.30 | 2019-2023 | |
| Abbvie INC. | $274.52 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $266.59 | 2023-2025 | Veozah |
| Mayne Pharma Commercial LLC | $228.14 | 2022-2025 | |
| Exeltis, USA INC. | $179.77 | 2019-2025 | Slynd |
| Allergan, INC. | $100.05 | 2019-2020 | |
| Coopersurgical, INC. | $93.98 | 2019-2023 | Paragard T 380a |
| Therapeuticsmd, INC. | $93.94 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $88.08 | 2019-2024 | |
| Agile Therapeutics, INC. | $86.15 | 2021-2023 | Twirla |
| Mylan Pharmaceuticals INC. | $82.01 | 2022 | |
| Millicent US INC | $73.14 | 2024 | Intrarosa, Femring |
| Medtronic, INC. | $67.71 | 2022-2023 | Truclear |
| Avion Pharmaceuticals | $67.56 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $41.50 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $32.43 | 2020-2024 | Aptima |
| Becton, Dickinson and Company | $29.30 | 2022 | |
| Minerva Surgical, INC | $28.62 | 2022-2023 | |
| Myovant Sciences INC. | $27.79 | 2021 | |
| Organon LLC | $26.36 | 2023 | Nexplanon |
| Merck Sharp & Dohme LLC | $20.94 | 2024 | Gardasil, Gardasil 9 |
| Lupin INC. | $19.00 | 2020 | |
| Exact Sciences Corporation | $17.87 | 2025 | |
| Shield Therapeutics INC | $16.18 | 2024 | |
| Scynexis, INC. | $12.74 | 2022 | |
| Mission Pharmacal Company | $12.28 | 2019 | |
| Dysis Medical, INC. | $11.31 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Warner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.